Select transition zone prostate cancers may be radiocurable despite markedly elevated prostate-specific antigen levels

A V D'Amico; I Kaplan

doi:10.1016/0167-8140(95)01675-9

Select transition zone prostate cancers may be radiocurable despite markedly elevated prostate-specific antigen levels

Radiother Oncol. 1996 Jan;38(1):73-6. doi: 10.1016/0167-8140(95)01675-9.

Authors

A V D'Amico¹, I Kaplan

Affiliation

¹ Department of Radiation Oncology, Harvard Medical School, North Dartmouth, MA 02747, USA.

PMID: 8850429
DOI: 10.1016/0167-8140(95)01675-9

Abstract

In 1993, three men with transition zone prostate cancers were described (Stamey et al., J. Urol. 149: 510-515, 1993) who despite high prostate-specific antigen (PSA) levels remained PSA failure-free at 22 months postoperatively. This report illustrates that prolonged PSA failure free survival may be achieved when external beam radiation therapy is used to treat similar patients.

MeSH terms

Actuarial Analysis
Adenocarcinoma / blood
Adenocarcinoma / pathology
Adenocarcinoma / radiotherapy*
Disease-Free Survival
Follow-Up Studies
Humans
Male
Neoplasm Staging
Prostate-Specific Antigen / blood*
Prostatic Neoplasms / blood
Prostatic Neoplasms / pathology
Prostatic Neoplasms / radiotherapy*
Radiotherapy Dosage
Radiotherapy, High-Energy*
Retrospective Studies

Substances

Prostate-Specific Antigen